How Pharmacists Could Be Key to Addressing the Opioid Crisis
The economic burden of Opioid Use Disorder (OUD) in the United States is staggering, reaching an estimated $2.7 trillion in 2023. While medications for OUD (MOUD) are effective, the real challenge lies in adherence. A recent study published in Frontiers in Public Health reveals a massive financial incentive for keeping patients on long-acting injectable buprenorphine (BUP-XR), and it points to a clear solution: empowering community pharmacists.
The "Cost of Consistency"
The study analyzed 661 patients and found a dramatic difference in healthcare spending based on treatment adherence. Patients who were adherent (PDC > 0.8) to BUP-XR (brand name Sublocade®) saved the healthcare system an average of $15,017 per person, per year compared to those who were adherent to other MOUDs but not the injectable.
These savings weren't theoretical—they came from a significant reduction in:
Emergency Department (ED) visits
Inpatient hospital admissions
Detoxification events
While patients adherent to BUP-XR had higher pharmacy costs due to the medication itself, their non-medication medical costs were significantly lower. Essentially, the injection provides stable buprenorphine levels that mitigate withdrawal and cravings more effectively than daily-dose alternatives, preventing costly medical crises.
The Adherence Gap
Despite these benefits, the study found that only 24.7% of patients remained adherent to BUP-XR over a 12-month period. Why? The barriers are often logistical:
Care Fragmentation: Navigating different providers for prescriptions and injections.
Access Challenges: Transportation issues, scheduling conflicts, and "pharmacy stock shortages".
Why We Should Pay Pharmacists to Administer BUP-XR
Community pharmacies are the most accessible points in the healthcare system, with extended hours and locations that reduce travel hurdles. With the SUPPORT for Patients and Communities Reauthorization Act of 2025 creating a federal pathway for pharmacists to prescribe and manage buprenorphine, the infrastructure is already being built.
By paying pharmacists a dedicated administration fee to provide BUP-XR on-site, payers can:
Eliminate Fragmentation: One stop for both the prescription and the injection.
Ensure Timely Dosing: Proactive care coordination in a community setting prevents the "gaps" that lead to relapse.
Massive ROI: Spending a small fee for a pharmacist’s time is a logical investment when the alternative is a $15,000 increase in acute care costs per patient.
To turn the tide on the opioid epidemic, we must move treatment from fragmented clinics to the heart of the community. Paying pharmacists to administer BUP-XR isn't just good medicine—it’s a multi-billion dollar economic necessity.
